tirzepatide obstructive sleep apnea fda approval 2024 FDA's First GLP-1 for May Reduce Reliance on CPAP In 2024, Zepbound (tirzepatide) became

doi:10.1210/clinem/dgaa863

Similar results were observed for a composite of the kidney-specific components of the primary outcome (HR 0.79, 95% CI 0.660.94) and for death from cardiovascular causes (HR 0.71, 95% CI 0.560.89)

341: c2701

In general, semaglutide (Wegovy ) and tirzepatide (Zepbound ) are FDA-approved for weight loss in people with: A BMI of 30 or higher , or A BMI of 27 or higher with at least one weight-related condition, like type 2 diabetes or high blood pressure Each medication also has additional FDA-approved uses beyond weight loss: Wegovy is also approved to reduce the risk of major cardiovascular events like heart attack and stroke in adults with cardiovascular disease

Brand-name alternatives Brand-name tirzepatide (Mounjaro for diabetes, Zepbound for weight management) eliminates compounding quality concerns entirely

Where is the best place to inject tirzepatide